Pamela Vig, Ph.D., is chief scientific officer for Mirum Pharmaceuticals, where she leads the scientific and clinical aspects of drug development and research, and medical affairs.
Pam has more than 25 years of industry experience in clinical development, medical affairs and translational science in various liver diseases including hepatitis B (HBV), hepatitis C (HCV), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cholestatic liver disease, as well as HIV and other infectious diseases. Before joining Mirum, Pam held leadership roles at Allergan plc and Tobira Therapeutics as vice president of clinical research and discovery, as well as vice president of clinical research at Presidio Pharmaceuticals, Inc. Pam previously served as director, global medical affairs, at Johnson & Johnson in London, UK, and also held positions in clinical research and development at Idenix Pharmaceuticals and Gilead Sciences, Inc. Pam is a member of the PSC Forum Steering Committee as well as co-chair for the pediatric cholestatic disease working group under the Forum for Collaborative Research.
Pam holds a Ph.D. from Imperial College London in the departments of hepatology and histopathology.
How old is Pamela Vig?
Dr. Vig is currently 53 years old. There are 6 older executives and no younger executives at Mirum Pharmaceuticals. The oldest executive at Mirum Pharmaceuticals is Mr. Eric H. Bjerkholt M.B.A., Chief Financial Officer, who is 64 years old. Learn More on Pamela Vig's age.
How do I contact Pamela Vig?
Has Pamela Vig been buying or selling shares of Mirum Pharmaceuticals?
Pamela Vig has not been actively trading shares of Mirum Pharmaceuticals within the last three months. Most recently, Pamela Vig sold 1,364 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $19.26, for a transaction totalling $26,270.64. Learn More on Pamela Vig's trading history.
Who are Mirum Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Mirum Pharmaceuticals?
During the last twelve months, Mirum Pharmaceuticals insiders bought shares 5 times. They purchased a total of 166,678 shares worth more than $4,424,479.85. During the last twelve months, insiders at the sold shares 14 times. They sold a total of 56,827 shares worth more than $1,621,582.31. The most recent insider tranaction occured on March, 27th when CFO Eric Bjerkholt bought 2,000 shares worth more than $49,600.00. Insiders at Mirum Pharmaceuticals own 24.1% of the company.
Learn More about insider trades at Mirum Pharmaceuticals. Information on this page was last updated on 3/27/2024.
